Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, which are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination with PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade.
Bapotulimab, a therapeutic antibody targeting ILDR2, is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma. Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused on addressing various mechanisms of immune resistance, and COM503, a high affinity antibody that blocks the interaction between IL-18 binding protein and IL-18.
The company has a collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.
It has a license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products, and with Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
